KIVU BIOSCIENCE

Accelerating development of kinder and gentler next-generation ADCs

Founded 2024 · $92.0M raised

Employees
11–50
Founded
2024
Business Model
B2B
Total Funding
$92.0M
Last Round
$92.0M Series AOct 2024
Rounds
1

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Kivu Bioscience develops next-generation antibody-drug conjugates (ADCs) for oncology, using proprietary linker-payload technology intended to deliver more precise cancer treatments with improved safety and tolerability. The company rapidly advances programs toward clinical proof of concept, collaborating with global partners and key opinion leaders. Its pipeline includes KIVU-107 targeting PTK7 and KIVU-305 targeting CEACAM5 for solid tumors, along with additional undisclosed ADC candidates. Based in San Mateo, the team focuses on kinder, gentler ADCs designed to help patients live longer.

Summary

KIVU BIOSCIENCE is a Biotech company, founded in 2024. It has raised $92.0M in total across 1 round, most recently a $92.0M Series A round in Oct 2024. Investors include Novo Holdings A/S, Gimv and Red Tree Venture Capital.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AOct 2024
$92.0M

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

KIVU BIOSCIENCE on Indexed.vc
<a href="https://indexed.vc/companies/kivu-bioscience"><img src="https://indexed.vc/api/badge/company/kivu-bioscience" alt="KIVU BIOSCIENCE on Indexed.vc" width="260" height="76" /></a>